CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 130 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 2.94 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $478,745 | +8.0% | 32,109 | -20.7% | 0.00% | 0.0% |
| Q2 2023 | $443,333 | +1036.8% | 40,487 | +282.7% | 0.00% | – |
| Q3 2021 | $39,000 | -92.5% | 10,578 | -88.3% | 0.00% | -100.0% |
| Q4 2020 | $518,000 | +1338.9% | 90,221 | +392.1% | 0.00% | – |
| Q4 2019 | $36,000 | -79.2% | 18,335 | -16.6% | 0.00% | – |
| Q4 2018 | $173,000 | -61.6% | 21,993 | -45.8% | 0.00% | – |
| Q3 2018 | $450,000 | -17.4% | 40,596 | +0.0% | 0.00% | -100.0% |
| Q2 2018 | $545,000 | – | 40,589 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,629,464 | $14,208,926 | 10.61% |
| Lynx1 Capital Management LP | 1,369,927 | $11,945,763 | 9.96% |
| Versant Venture Management, LLC | 543,753 | $4,741,526 | 9.88% |
| Foresite Capital Management IV, LLC | 1,787,094 | $15,583,460 | 8.09% |
| Octagon Capital Advisors LP | 4,570,918 | $39,858,405 | 5.74% |
| ACUTA CAPITAL PARTNERS, LLC | 878,500 | $7,660,520 | 5.64% |
| TCG Crossover Management, LLC | 3,048,257 | $26,580,801 | 5.18% |
| Affinity Asset Advisors, LLC | 1,083,118 | $9,444,789 | 3.12% |
| Altium Capital Management LP | 620,000 | $5,406,400 | 3.00% |
| Bain Capital Life Sciences Investors, LLC | 2,500,000 | $21,800 | 2.72% |